Science News, Information and Educational Resources



Science Feed Image

  •    


    Harbin Clinic CEO Dr. Ken Davis speaks to Rome Rotarians on Thursday about the clinic's new cancer center on East Second Avenue.
    www.topix.com   ...Read On



    In this video, Dr. Kenneth Ellenbogen talks about important information presented at the American Heart Association Scientific Sessions 2010. First he talked about the ROCKET AF clinical trial of rivaroxaban, a new drug that is an alternative to warfarin (Coumadin), as well as another alternative, the recently-approved dabigatran. He provided scenarios as to how these drugs may be used in conjunction with catheter ablation or surgery. He also talked about a clinical trial being presented there that found fish oil to not be beneficial for preventing atrial fibrillation. Watch the video at: Dr. Kenneth Ellenbogen on Stroke Prevention Drugs and Fish Oil for Atrial Fibrillation — Video Mellanie True Hills Bio
    feedproxy.google.com   ...Read On



    PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") announced today that the Dr. Ken Sokoll, Vice President Clinical Development and Chief Operating
    feeds.bignewsnetwork.com   ...Read On



    An Interview with the Hosts of YCC Answers with Dr. Edward Chu and Dr. Ken Miller October 21, 2007 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095
    www.yalecancercenter.org Full Story  ...Read On




    Harbin physician receives Georgia Cancer Coalition grant for clinical research
    Rome News Tribune
    “We are very excited about this designation honoring Dr. Matt Mumber and his dedication to cancer research,” said Dr. Ken Davis, Harbin Clinic President and

        ...Read On



       
    You can link to this article on your web site using following code:

    Website Code:

    Forum Code:  




     
     
    Comments

    We're looking for comments that are interesting, substantial or highly amusing. If your comments are excessively self-promotional (use your real name, no keywords please), obnoxious, or even worse, boring, you will be banned from commenting. Your comment must be related to the post. Please do not comment on how great or wonderful the post is. All comments are moderated and, if approved, will display in less than 24 hours.


    blog comments powered by Disqus